Health and Human Services Secretary Robert F. Kennedy Jr. and Food and Drug Administration (FDA) Commissioner Marty Makary ...

President Donald Trump’s top health advisers announced a push to cut health costs by bringing more cutting-edge generic drugs ...

The FDA said it proposed significant changes to simplify biosimilarity studies and reduce what it described as unnecessary ...

The FDA has revealed a set of measures designed to increase the availability of biosimilars in the U.S. and in turn reduce ...

The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. SAN DIEGO — At AdvaMed’s annual conference, top medical ...

The Food and Drug Administration (FDA) is launching an effort to streamline the approval process for cheaper alternative “biosimilar” versions of biologic drugs as a way to curb health costs.  The ...

Senators cite study showing 22 times higher serious side effects from chemical abortion drugs than FDA labels indicate, ...

Generic versions of biologic drugs could hit the market without human trials and allow the market forces to bring down costs, ...

Health and Human Services Secretary Robert F. Kennedy Jr., and Food and Drug Administration (FDA) Commissioner Marty Makary ...